[ Price : $8.95]
Physician Douglas Smith petitions FDA to take 11 steps to curtail the use of the indications of opioid addiction and opioid use di...[ Price : $8.95]
ZyVersa Therapeutics says a new regulatory development could significantly shorten the path to approval for treatments targeting f...[ Price : $8.95]
Three former FDAers warn of a slow-moving catastrophe coming for the agency as it loses staff and resources under leaders who have...[ Price : $8.95]
FDA approves Bristol Myers Squibbs combination of Opdivo (nivolumab) with Yervoy (ipilimumab) for treating certain adult and pedia...[ Price : $8.95]
FDA warns Lawrenceville, NJ-based EpiCare Acquisitions about Quality System and other violations in its manufacturing of a family ...[ Price : $8.95]
Bausch + Lomb recalls its enVista intraocular lenses after the company received reports of complications, which it says could not ...[ Price : $8.95]
Six Sidley attorneys raise several practical questions arising from a Texas federal court decision finding that FDA does not have ...[ Price : $8.95]
Rhythm Pharmaceuticals announces positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for tr...